|
|
Rescriptor (Delavirdine)
| Brand Name: |
Rescriptor |
| Generic Name: |
Delavirdine, DLV |
| Adult Single Dose: |
Two 200-mg tablets (three times a
day) OR four 100-mg tablets (three times a day) |
| Food & Liquid Restrictions: |
None |
| Drug Class: |
NNRTI |
The Basics
- An Overview of Rescriptor (Delavirdine) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
- Delavirdine (Rescriptor) (May 18, 2008)
To read PDF, click here
From AIDS InfoNet
- Rescriptor (Delavirdine, DLV) (January/February 2008)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Rescriptor (Delavirdine) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Delavirdine (Rescriptor) (November 13, 2006)
From AIDSMeds.com
- Patient Information About Rescriptor (Delavirdine) (PDF) (June 2006)
From Pfizer, Inc.
- Rescriptor (Delavirdine) (May 2005)
To read PDF, click here
From The Center for AIDS
- Drug Interactions: Delavirdine (August 2004)
From Project Inform
News
Research
- Women and Pharmacology: Delavirdine Study (March 2001)
In Project Inform Perspective, from Project Inform
- Therapeutic Drug Monitoring of Amprenavir Combined With Ritonavir as Salvage Therapy in HIV-1-Infected Patients (July 11, 2000)
In The XIII International AIDS Conference, from The Body PRO
- ACTG 359: A Chain Reaction of Unintended Consequences (July 2000)
Unexpected adefovir/delavirdine interaction found to reduce delavirdine/saquinavir levels.
In TAGline, from Treatment Action Group
- Continued Lamivudine (3TC) vs. Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Patients: 48-Week Follow-Up of ACTG 370 (February 1, 2000)
In The 7th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Delavirdine Combination and Viral Load (October 17, 1997)
In AIDS Treatment News, from AIDS Treatment News
- Antiretroviral Drug Interaction Studies Show Favorable Effects (January 1997)
Includes a brief look at drug-interaction studies for delavirdine-saquinavir and delavirdine-indinavir.
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Delavirdine Disappoints at FDA (January 1997)
In TAGline, from Treatment Action Group
|
|
